Clinical trials: Movement Abnormalities
Deep Brain Stimulation, Parkinson Disease
Visualization of the STN and GPi for DBS
The purpose of the study is to determine if using SIS System for DBS planning results in less distance between the planned target location and the actual implanted lead location than DBS planning without SIS System.
- Trial name
- VISION (NCT05774041)
- Testing
- SIS System
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Surgical Information Sciences Inc.
Myoclonus
Pilot Efficacy Study of T2000 in Myoclonus Dystonia
This pilot study will evaluate the safety and efficacy of once daily T2000 when used to treat patients with Myoclonus Dystonia over a 12 week period.
- Trial name
- NCT00506012
- Testing
- T2000
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Parkinson's Disease
PET Study in Parkinson's Disease Patients
This is a multi-centre study to be conducted in Sweden and Finland. Up to 24 male and/or female patients of non-childbearing potential aged 45 to 75 years (inclusive), with a clinical diagnosis Parkinson's Disease will be…
- Trial name
- NCT01527695
- Testing
- ER tablet 25 mg AZD3241, ER tablet 100 mg AZD3241
- Where
- 3 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Intellectual Disability, Developmental Delay
Biomarker for Creatine Deficiency Syndromes (BioCDS)
Development of a new mass spectrometry-based biomarker for the ear-ly and sensitive diagnosis of the Creatine Deficiency Syndromes from dry-blood-spot sample
- Conditions
- Intellectual Disability, Developmental Delay, Movement Disorder, Behavioral Disorder
- Trial name
- BioCDS (NCT02934854)
- Where
- 4 sites in Egypt, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Parkinson Disease
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25…
- Trial name
- NCT06722729
- Testing
- KDT-3594
- Where
- Japan
- Volunteers
- 178 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Parkinson Disease
Temporally Optimized Patterned Stimulation (TOPS®) Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease
This study will test newly developed stimulation settings called Temporally Optimized Patterned Stimulation or TOPS, which can be used with an already implanted deep brain stimulation system.
- Trial name
- TOPS (NCT04390867)
- Testing
- TOPS1 DBS, TOPS2 DBS, TOPS3 DBS
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Deep Brain Innovations LLC
Parkinson Disease
Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients
This study is implemented to identify factors having an impact on improvement or exacerbation of non-motor symptoms, to provide information contributing to development of medical care in this field and improvement of patients'…
- Trial name
- J-FIRST (NCT02073981)
- Where
- Japan
- Volunteers
- 1,021 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease
Effect of Opicapone at Steady State on Warfarin Pharmacokinetics
Single-centre, open-label, fixed-sequence design consisting of 2 periods separated by a washout period of at least 14 days.
- Trial name
- NCT02305030
- Testing
- BIA 9-1067, Warfarin
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Special Survey on PD Patients With Renal Dysfunction
The survey is conducted to collect safety and effectiveness information targeting patients who have both Parkinson's disease and renal dysfunction treated with Pramipexole in the daily clinical settings in Japan.
- Trial name
- NCT00613756
- Where
- 98 sites in Japan
- Volunteers
- 107 people
- Sponsor
- Boehringer Ingelheim
Progressive Supranuclear Palsy
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
The purpose of this study is to evaluate the safety and tolerability of multiple ascending intravenous infusions of BMS-986168 and to assess the pharmacokinetics and immunogenicity of BIIB092, and pharmacodynamics of BIIB092 on…
- Trial name
- CN002-003 (NCT02460094)
- Testing
- BIIB092
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- Biogen
Parkinson's Disease
Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)
This study is being done to assess the pharmacokinetics of SCH 900800 in participants with moderate to severe Parkinson's Disease (PD) being treated with L-DOPA.
- Trial name
- NCT01500707
- Testing
- SCH 900800
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
This study is to evaluate the effictiveness and safety of Ly03003 following intramuscular injections
- Trial name
- NCT04571164
- Testing
- LY03003(Rotigotine,extended-release microspheres)
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson's Disease
Deep Brain Stimulation Effects Study
The purpose of this study is to provide proof-of-concept that the test product can perform as intended in an intra-operative setting and the responses to the test product are perceivable in a person.
- Trial name
- NCT01098565
- Testing
- Study device HFR0001
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- MedtronicNeuro
Parkinson's Disease
Single Ascending Dose Study of PRX002 in Healthy Subjects
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.
- Trial name
- NCT02095171
- Testing
- PRX002
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Prothena Biosciences Limited
Supranuclear Palsy, Progressive
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of…
- Trial name
- PASSPORT (NCT03068468)
- Testing
- BIIB092
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 490 people
- Sponsor
- Biogen
Parkinson's Disease
A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- ProParkB (NCT07382440)
- Where
- 12 sites in Belgium
- Volunteers
- 120 people
- Sponsor
- AbbVie
Dyskinesia, Cerebral Palsy
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
- Trial name
- NCT05206513
- Testing
- Valbenazine
- Where
- 38 sites in United States, Argentina and 8 more
- Volunteers
- 86 people
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease
Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease
The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.
- Trial name
- PD (NCT01032486)
- Testing
- Rasagiline mesylate
- Volunteers
- 120 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Tourette Syndrome
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a…
- Trial name
- NCT03325010
- Testing
- Valbenazine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 127 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
OpicApone Sleep dISorder
The aim of this study is to To investigate in an exploratory manner the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's…
- Trial name
- OASIS (NCT04986995)
- Testing
- Opicapone
- Where
- Portugal
- Volunteers
- 22 people
- Sponsor
- Bial - Portela C S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.